Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Berman

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Cancer Immunity|November 25, 2010
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanomaDavid Berman, Susan M Parker, Jonathan Siegel, et al.
International Journal of Oncology|December 4, 2009
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancerSoner Altiok, Heather Mezzadra, Sanjay Jagannath, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanomaJeffrey S Weber, Omid Hamid, Scott D Chasalow, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation studyPaul G Richardson, Asher A Chanan-Khan, Melissa Alsina, et al.
Journal of Translational Medicine|March 26, 2013
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsVafa Shahabi, David Berman, Scott D Chasalow, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myelomaPaul G Richardson, Ashraf Z Badros, Sundar Jagannath, et al.
Pediatrics in Review|September 6, 2005
Index of suspicionBeng R Fuh, Esther E Forrster, Monica Pourrat, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson, Omid Hamid, David Minor, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|January 3, 2013
Prospective multicenter clinical trial of a minimally invasive temperature-controlled bipolar fractional radiofrequency system for rhytid and laxity treatmentMacrene Alexiades-Armenakas, James Newman, Andrea Willey, et al.
European Urology Open Science|August 2, 2021
Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysisSidra Khalid, Bassam Mohammed Basulaiman, Jeffrey Emack, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Cancer Immunity|November 25, 2010
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanomaDavid Berman, Susan M Parker, Jonathan Siegel, et al.
International Journal of Oncology|December 4, 2009
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancerSoner Altiok, Heather Mezzadra, Sanjay Jagannath, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanomaJeffrey S Weber, Omid Hamid, Scott D Chasalow, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation studyPaul G Richardson, Asher A Chanan-Khan, Melissa Alsina, et al.
Journal of Translational Medicine|March 26, 2013
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsVafa Shahabi, David Berman, Scott D Chasalow, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myelomaPaul G Richardson, Ashraf Z Badros, Sundar Jagannath, et al.
Pediatrics in Review|September 6, 2005
Index of suspicionBeng R Fuh, Esther E Forrster, Monica Pourrat, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson, Omid Hamid, David Minor, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|January 3, 2013
Prospective multicenter clinical trial of a minimally invasive temperature-controlled bipolar fractional radiofrequency system for rhytid and laxity treatmentMacrene Alexiades-Armenakas, James Newman, Andrea Willey, et al.
European Urology Open Science|August 2, 2021
Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysisSidra Khalid, Bassam Mohammed Basulaiman, Jeffrey Emack, et al.
Pageof 6